BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Traub J, Häusser-Kinzel S, Weber MS. Differential Effects of MS Therapeutics on B Cells-Implications for Their Use and Failure in AQP4-Positive NMOSD Patients. Int J Mol Sci 2020;21:E5021. [PMID: 32708663 DOI: 10.3390/ijms21145021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 J Tullman M, Zabeti A, Vuocolo S, Dinh Q. Inebilizumab for treatment of neuromyelitis optica spectrum disorder. Neurodegener Dis Manag 2021;11:341-52. [PMID: 34486379 DOI: 10.2217/nmt-2021-0017] [Reference Citation Analysis]
2 Liu C, Shi M, Zhu M, Chu F, Jin T, Zhu J. Comparisons of clinical phenotype, radiological and laboratory features, and therapy of neuromyelitis optica spectrum disorder by regions: update and challenges. Autoimmun Rev 2021;:102921. [PMID: 34384938 DOI: 10.1016/j.autrev.2021.102921] [Reference Citation Analysis]
3 Helmchen C, Buttler GM, Markewitz R, Hummel K, Wiendl H, Boppel T. Acute bilateral optic/chiasm neuritis with longitudinal extensive transverse myelitis in longstanding stable multiple sclerosis following vector-based vaccination against the SARS-CoV-2. J Neurol 2021. [PMID: 34131771 DOI: 10.1007/s00415-021-10647-x] [Reference Citation Analysis]
4 Maciak K, Pietrasik S, Dziedzic A, Redlicka J, Saluk-Bijak J, Bijak M, Włodarczyk T, Miller E. Th17-Related Cytokines as Potential Discriminatory Markers between Neuromyelitis Optica (Devic's Disease) and Multiple Sclerosis-A Review. Int J Mol Sci 2021;22:8946. [PMID: 34445668 DOI: 10.3390/ijms22168946] [Reference Citation Analysis]
5 Traub J, Husseini L, Weber MS. B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders. Pharmaceuticals (Basel) 2021;14:37. [PMID: 33419217 DOI: 10.3390/ph14010037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]